Subscribe
dentist_istock-532326710_pyotr021
pyotr021 / iStockphoto.com
22 February 2018Big Pharma

J&J to boost medical device division with acquisition

Johnson & Johnson (J&J) has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court